sodium stibogluconate

Phase 2Small molecule

DDrugs for Neglected Diseases

sodium stibogluconate is one of 147 small molecule programs targeting Leishmaniasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

146

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeishmaniasisActive, not recruiting

Cutaneous LeishmaniasisActive, not recruiting

LymphomaActive, not recruiting

Visceral LeishmaniasisActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

MelanomaActive, not recruiting

LeishmaniasisPhase 2

Active, not recruiting

Cutaneous LeishmaniasisPhase 2

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Visceral LeishmaniasisPhase 2

Active, not recruiting

Myelodysplastic SyndromePhase 1

Active, not recruiting

MelanomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

sodium stibogluconate

DDrugs for Neglected Diseases

Phase 2

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Tafasitamab

Incyte

Preclinical

7 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Systemic Therapy

1 8

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 9

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

2 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Not yet recruiting

Cutaneous Leishmaniasis

NCT07463040

Clinical

Trials by Indication[1]

Cutaneous Leishmaniasis6 trials

Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India

Completed·—·Phase 4·NCT01661296·100 enrolled

A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis

Completed·AAccess to Advanced Health Institute (AAHI)·Phase 2·NCT01011309·45 enrolled

Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients

Completed·WWaisenmedizin e. V. Promoting Access to Essential Medicine·Phase 2·NCT00996463·63 enrolled

Show 3 more trials

Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate

Recruiting·—·Phase 2·NCT06798402·80 enrolled

Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)

Not yet recruiting·IInstitute of Tropical Medicine, Belgium·Phase 3·NCT07463040·900 enrolled

Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT00884377·56 enrolled

Leishmaniasis4 trials

Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis

Completed·DDrugs for Neglected Diseases·Phase 3·NCT00255567·1,142 enrolled

Use of Sodium Stibogluconate as a Treatment for Leishmaniasis

Completed·UU.S. Army Medical Research and Development Command·Phase 1/2·NCT00657618·77 enrolled

Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

No longer available·UUniversity of California, San Francisco··NCT00508963

Show 1 more trial

Sodium Stibogluconate Treatment of Leishmaniasis

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT00662012·414 enrolled

Visceral Leishmaniasis2 trials

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

Completed·DDrugs for Neglected Diseases·Phase 2·NCT05957978·52 enrolled

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Completed·DDrugs for Neglected Diseases·Phase 3·NCT03129646·439 enrolled

Melanoma1 trial

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

Completed·—·Phase 1·NCT00498979·22 enrolled

Lymphoma1 trial

Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

Terminated·TThe Cleveland Clinic·Phase 1·NCT00311558·18 enrolled

3 more indications

p53 Mutations1 trial

Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations

Unknown status·FFirst Affiliated Hospital of Jinan University·Phase 2·NCT04906031·5 enrolled

Myelodysplastic Syndrome1 trial

Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome

Terminated·NNorthwestern University·Phase 1·NCT01009502·1 enrolled

Advanced Malignancies1 trial

Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00629200·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for sodium stibogluconate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — sodium stibogluconate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for sodium stibogluconate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Drugs for Neglected Diseases company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDrugs for Neglected Diseases

sodium stibogluconate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Cutaneous Leishmaniasis6 trials

Leishmaniasis4 trials

Visceral Leishmaniasis2 trials

Melanoma1 trial

Lymphoma1 trial

p53 Mutations1 trial

Myelodysplastic Syndrome1 trial

Advanced Malignancies1 trial

References

Drug Info

Quick Facts

Related News